Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn's disease: 5-year follow-up of the PROFILE trial

医学 病历 意向治疗分析 临床试验 随机对照试验 物理疗法 疾病 外科 随机化 比例危险模型 儿科 住院 患者数据 急诊医学 试用登记 回顾性队列研究 生存分析 内科学 需要治疗的数量 临床终点 危险系数 置信区间 安全概况 梅德林 年轻人 前瞻性队列研究
作者
Nurulamin M Noor,Mohmmed Tauseef Sharip,Haiyan Zheng,Barry Widmer,Biljana Brezina,Kamal V. Patel,Francis Dowling,Suhaylah Bhatti,Nadia Alsmade,Tariq Ahmad,Paul J.R. Banim,James Berrill,Rachel Cooney,Juan de la Revilla Negro,Shanika de Silva,Shahida Din,Dharmaraj Durai,John Nicholas Gordon,Ailsa L. Hart,Peter Miles Irving
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier BV]
卷期号:11 (11): 960-970 被引量:3
标识
DOI:10.1016/s2468-1253(26)00192-5
摘要

BACKGROUND: The PROFILE trial previously reported better 48-week outcomes for patients with Crohn's disease who received top-down anti-TNF treatment from diagnosis, compared with a conventional step-up strategy. Through subsequent follow-up of PROFILE participants, we aimed to assess whether the benefit of top-down treatment from diagnosis results in modification of the long-term disease course. METHODS: PROFILE was a multicentre, open-label, randomised controlled trial completed in 40 hospitals in the UK, which included patients aged 16-80 years with newly diagnosed Crohn's disease. Eligible patients were randomly assigned via a secure online platform to a top-down (infliximab plus immunomodulator) or a step-up protocolised treatment strategy for 48 weeks, after which participants reverted to local standards of care. Objective outcome data were extracted for up to 5 years after the week 48 visit, including need for Crohn's-related abdominal surgery as the primary outcome. Data were analysed based on the original PROFILE randomisation and intention-to-treat population. Participants without long-term follow-up data were censored at the week 48 visit. Time-to-event analyses were performed using the Kaplan-Meier method and Cox proportional hazards model. The trial was registered with the ISRCTN registry, number 11808228 and is complete. FINDINGS: Between Dec 29, 2017, and Jan 5, 2022, 483 patients were assessed for inclusion. 389 patients were enrolled and randomly assigned (three patients were excluded due to ineligibility), 193 to top-down treatment and 193 to step-up treatment. Of the 386 participants in the PROFILE primary trial, 358 (93%) had post-week 48 records available for review (182 [51%] top-down and 176 [49%] step-up). Median follow-up was approximately 5 years from randomisation (1809 days [IQR 1300-2101]), by which point 172 (89%) of 193 patients in the step-up group and 191 (99%) of 193 patients in the top-down group had received biological or immunomodulator therapy. Relating to the primary outcome, during follow-up there were 28 Crohn's disease-related abdominal surgeries in 26 patients treated with a step-up approach versus six surgeries in six patients treated with a top-down approach. Time to surgery was shorter in the step-up group than the top-down group (adjusted hazard ratio [aHR] 5·23 [95% CI 1·99-13·76]; p=0·0008). For the secondary outcomes, incidence of Crohn's disease-related hospital admissions was higher in patients originally managed with step-up treatment versus top-down treatment (41 [21%] of 193 patients vs 22 [11%] of 193 patients); and time to first hospital admission was shorter with step-up treatment than with top-down treatment (aHR 2·01 [95% CI 1·18-3·41], p=0·017). Progression to B2 or B3 complications was also more frequent in those originally managed with step-up treatment compared with top-down treatment (32 [17%] of 192 patients vs 13 [7%] of 193 patients); with time to disease progression being shorter in the step-up group than in the top-down group (aHR 2·46 [95% CI 1·25-4·86]; p=0·010). There was no difference in safety outcomes between groups for either serious infections (12 [6%] of 193 step-up patients and 14 [7%] of 193 top-down patients) or malignancies (five patients [3%] and three patients [2%] respectively). INTERPRETATION: Early top-down anti-TNF treatment from diagnosis was associated with improved long-term outcomes at 5 years compared with step-up treatment and is suggestive of a disease-modifying effect in Crohn's disease. FUNDING: Wellcome and Celltrion.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
pinst7完成签到,获得积分10
1秒前
1秒前
科研通AI2S的应助被momo采纳,获得10
2秒前
倩倩倩完成签到 ,获得积分10
2秒前
酷波er的应助被shan采纳,获得10
3秒前
Orange的应助被yyyyy采纳,获得10
3秒前
橙豆儿完成签到 ,获得积分10
3秒前
飘逸的山柏完成签到,获得积分10
5秒前
共享精神的应助被饭团采纳,获得10
5秒前
molihuakai的应助被糖糖采纳,获得30
6秒前
辛勤的乌发布了新的文献求助30
6秒前
7秒前
ZL完成签到,获得积分10
8秒前
8秒前
王佳瑶完成签到,获得积分10
8秒前
9秒前
9秒前
10秒前
嘛丝丝完成签到,获得积分10
10秒前
11秒前
富贵儿完成签到,获得积分10
11秒前
11秒前
科研通AI6.2的应助被孙某人采纳,获得30
11秒前
姜丝罐罐n完成签到 ,获得积分10
12秒前
13秒前
爱听歌的听荷完成签到,获得积分10
13秒前
GUESSSS发布了新的文献求助10
14秒前
15秒前
ainiyiwannian完成签到,获得积分10
15秒前
Mars完成签到,获得积分10
15秒前
16秒前
shan发布了新的文献求助10
17秒前
悦耳从波的应助被wang采纳,获得10
17秒前
小黑皮完成签到,获得积分10
18秒前
Beni完成签到,获得积分10
19秒前
边伯贤完成签到 ,获得积分10
19秒前
无花果的应助被谨慎的秋烟采纳,获得10
20秒前
眯眯眼的谷冬完成签到 ,获得积分10
20秒前
agog完成签到,获得积分10
20秒前
HYZJIA1完成签到 ,获得积分10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153668
求助须知:如何正确求助?哪些是违规求助? 9550448
关于积分的说明 21698499
捐赠科研通 7742484
什么是DOI,文献DOI怎么找? 3425564
关于科研通互助平台的介绍 2550698
邀请新用户注册赠送积分活动 2469211